These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 29034364)

  • 1. Microenvironmental agonists generate
    Jayappa KD; Portell CA; Gordon VL; Capaldo BJ; Bekiranov S; Axelrod MJ; Brett LK; Wulfkuhle JD; Gallagher RI; Petricoin EF; Bender TP; Williams ME; Weber MJ
    Blood Adv; 2017 Jun; 1(14):933-946. PubMed ID: 29034364
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of cyclin-dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma.
    Zhao X; Bodo J; Chen R; Durkin L; Souers AJ; Phillips DC; Hsi ED
    EJHaem; 2020 Jul; 1(1):161-169. PubMed ID: 35847704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia.
    Yi X; Jain N; Iles LR; Ayres ML; Wierda WG; Gandhi V
    Front Oncol; 2022; 12():833714. PubMed ID: 35273915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies.
    Melvold K; Giliberto M; Karlsen L; Ayuda-Durán P; Hanes R; Holien T; Enserink J; Brown JR; Tjønnfjord GE; Taskén K; Skånland SS
    Mol Oncol; 2022 Mar; 16(5):1153-1170. PubMed ID: 34861096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK-STAT signalling shapes the NF-κB response in CLL towards venetoclax sensitivity or resistance via Bcl-XL.
    Haselager MV; Thijssen R; Bax D; Both D; De Boer F; Mackay S; Dubois J; Mellink C; Kater AP; Eldering E
    Mol Oncol; 2023 Jun; 17(6):1112-1128. PubMed ID: 36550750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation.
    Thus YJ; De Rooij MFM; Swier N; Beijersbergen RL; Guikema JEJ; Kersten MJ; Eldering E; Pals ST; Kater AP; Spaargaren M
    Haematologica; 2023 Mar; 108(3):797-810. PubMed ID: 36226498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL.
    Haselager M; Thijssen R; West C; Young L; Van Kampen R; Willmore E; Mackay S; Kater A; Eldering E
    Cell Death Differ; 2021 May; 28(5):1658-1668. PubMed ID: 33495554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma.
    Dengler MA; Teh CE; Thijssen R; Gangoda L; Lan P; Herold MJ; Gray DH; Kelly GL; Roberts AW; Adams JM
    Oncogene; 2020 Feb; 39(9):2009-2023. PubMed ID: 31772331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLL.
    Jayappa KD; Gordon VL; Morris CG; Wilson B; Shetty BD; Cios KJ; Arora PC; Isaac KM; Saha S; Bender TP; Williams ME; Portell CA; Weber MJ
    Blood Adv; 2021 Sep; 5(17):3497-3510. PubMed ID: 34432864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EP4 receptor agonist L-902688 augments cytotoxic activities of ibrutinib, idelalisib, and venetoclax against chronic lymphocytic leukemia cells.
    Nabergoj S; Markovič T; Avsec D; Gobec M; Podgornik H; Jakopin Ž; Mlinarič-Raščan I
    Biochem Pharmacol; 2021 Jan; 183():114352. PubMed ID: 33278351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199.
    Bojarczuk K; Sasi BK; Gobessi S; Innocenti I; Pozzato G; Laurenti L; Efremov DG
    Blood; 2016 Jun; 127(25):3192-201. PubMed ID: 27095788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.
    Ondrisova L; Mraz M
    Front Oncol; 2020 Oct; 10():591577. PubMed ID: 33154951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia.
    Sarapura Martinez VJ; Buonincontro B; Cassarino C; Bernatowiez J; Colado A; Cordini G; Custidiano MDR; Mahuad C; Pavlovsky MA; Bezares RF; Favale NO; Vermeulen M; Borge M; Giordano M; Gamberale R
    Front Oncol; 2023; 13():1143881. PubMed ID: 37020867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma.
    Portell CA; Wages NA; Kahl BS; Budde LE; Chen RW; Cohen JB; Varhegyi NE; Petroni GR; Williams ME
    Blood Adv; 2022 Mar; 6(5):1490-1498. PubMed ID: 34700344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIK-75 overcomes venetoclax resistance
    Huang S; Liu Y; Chen Z; Wang M; Jiang VC
    Am J Cancer Res; 2022; 12(3):1102-1115. PubMed ID: 35411248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States.
    Chatterjee A; Shapouri S; Manzoor BS; Ravelo A; Sail K; Qendri V; van de Wetering G; Davids MS
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1532-1544. PubMed ID: 34714110
    [No Abstract]   [Full Text] [Related]  

  • 17. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells.
    Oppermann S; Ylanko J; Shi Y; Hariharan S; Oakes CC; Brauer PM; Zúñiga-Pflücker JC; Leber B; Spaner DE; Andrews DW
    Blood; 2016 Aug; 128(7):934-47. PubMed ID: 27297795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
    Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
    Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance.
    Kapoor I; Bodo J; Hill BT; Hsi ED; Almasan A
    Cell Death Dis; 2020 Nov; 11(11):941. PubMed ID: 33139702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.